Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-02	€1.140	+0.44%	23,000
26-09-01	€1.135	-1.30%	23,000
26-08-31	€1.150	0.00%	21,000
26-08-28	€1.150	+1.32%	17,000
26-08-27	€1.135	-0.44%	8,000

Real-time Borsa Italiana

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Borsa Italiana 11:45:00 2026-09-02 EDT			5-day change	1st Jan Change
1.140 ^EUR	+0.44%		0.00%	-22.45%

08-31	Milan in the pink at the open, oil stocks lead the MIB	AN
08-31	Futures weak; Brent higher after US-Iran attacks	AN

Market Cap	9.67M 11.21M 9.11M 8.3M 15.51M 1.06B 15.63M 108M 41.86M 541M 42.09M 41.17M 1.78B	P/E 2024	30.8x	P/E 2025	17x
Enterprise Value	9.97M 11.55M 9.39M 8.55M 15.99M 1.09B 16.11M 111M 43.13M 558M 43.38M 42.43M 1.83B	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	33.31%	Yield 2024 *	-	Yield 2025	-

08-31	Milan in the pink at the open, oil stocks lead the MIB	AN
08-31	Futures weak; Brent higher after US-Iran attacks	AN
08-28	Buying across Europe, Lottomatica goes all-in on the MIB	AN
08-28	Europe pushes higher at the halfway mark, MIB at 52,700	AN
08-27	Laboratorio Farmaceutico Erfo closes half-year with revenue up 2%	AN
08-27	Milan opens lower; STM jumps after Nvidia earnings	AN
08-26	Piazza Affari ends higher, Buzzi leads the MIB	AN
07-06	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
06-29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN
06-22	Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares	AN
06-19	Laboratorio Farmaceutico Erfo S.p.A.'s Equity Buyback announced on December 18, 2024, has expired.	CI
06-15	Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares	AN
06-04	Equities trend higher; banks lead gains on the MIB	AN

04-09	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
25-10-21	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
25-08-29	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
25-06-04	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
25-05-19	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

Laboratorio Farmaceutico Erfo S.p.A. Stock

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation : Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases : Laboratorio Farmaceutico Erfo S.p.A.

News in other languages : Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Price Extremes

Managers and Directors : Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08-31	Milano maglia rosa in avvio; sul MIB guidano le oil
08-31	Futures deboli; Brent su dopo attacchi USA-Iran
08-28	Buy in tutta Europa, Lottomatica fa all-in sul MIB
08-28	Europee di slancio al giro di boa; MIB a 52.700
08-27	Laboratorio Farmaceutico Erfo archivia semestre con ricavi su del 2%

1 day	+0.44%
Current month	-0.87%
1 month	-2.98%
3 months	+3.64%
6 months	-5.79%
Current year	-22.45%

1 week	1.11	1.18
1 month	1.08	1.18
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	56	2012-12-31
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	56	2012-12-31
Flavio Corpina BRD	Director/Board Member	47	2016-12-31
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/16/25	Alessandro Cutè	Sell	Chief Executive Officer	968,000	10.7556%
12/16/25	Alessandro Cutè	Sell	Chief Executive Officer	322,000	3.5778%
6/29/22	Alessandro Cutè	Others	Chief Executive Officer	300,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	+0.44%	0.00%	-28.30%	-2.56%	11.21M
ELI LILLY AND COMPANY	+0.44%	-2.16%	+58.29%	+108.49%	1,034B
JOHNSON & JOHNSON	+1.18%	+1.90%	+54.52%	+71.23%	654B
ABBVIE INC.	+0.28%	-0.88%	+22.97%	+78.36%	459B
ROCHE HOLDING AG	+0.49%	-5.19%	+33.28%	+35.53%	343B
NOVARTIS AG	+0.27%	+3.26%	+29.76%	+47.50%	307B
ASTRAZENECA PLC	+0.12%	-2.11%	+0.60%	+12.03%	251B
AMGEN INC.	+0.50%	-0.13%	+53.27%	+73.13%	237B
NOVO NORDISK A/S	+2.64%	-1.08%	-15.85%	-53.97%	202B
GILEAD SCIENCES, INC.	-0.09%	+1.09%	+32.83%	+99.19%	186B
Average	+0.59%	-2.55%	+24.14%	+46.89%	367.16B
Weighted average by Cap.	+0.48%	-3.31%	+38.86%	+67.92%

	2024	2025
Net sales	6.03M 6.99M 5.68M 5.18M 9.68M 661M 9.75M 67.28M 26.11M 338M 26.26M 25.68M 1.11B	9.73M 11.28M 9.17M 8.35M 15.61M 1.07B 15.73M 109M 42.12M 545M 42.36M 41.43M 1.79B
Net income	353K 409K 332K 303K 566K 38.63M 570K 3.93M 1.53M 19.75M 1.54M 1.5M 64.88M	737K 854K 694K 633K 1.18M 80.7M 1.19M 8.22M 3.19M 41.26M 3.21M 3.14M 136M
Net Debt	5.77K 6.68K 5.43K 4.95K 9.25K 631K 9.32K 64.32K 24.96K 323K 25.1K 24.55K 1.06M	295K 342K 278K 254K 474K 32.35M 477K 3.29M 1.28M 16.54M 1.29M 1.26M 54.33M